Slaughter and May advised on automotive deals worth a total of $2.3bn while Kirkland & Ellis led by volume with a total of eight deals.
Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback